Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

NCT01549964 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

916

Enrollment

INDUSTRY

Sponsor class

Stopped Due to concerns about potential liver safety (See Detailed Description)

Conditions

Glycemic Control

Interventions

DRUG: Fasiglifam (TAK-875)
DRUG: Sitagliptin
DRUG: Placebo

Sponsor

Takeda